CFI-400936
CFI-400936 is a potent TTK inhibitor with an IC50 of 3.6 nM. CFI-400936 has antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 1338793-07-9
- Formula: C25H27N5O3S
- Molecular Weight:477.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | GI50 |
0.16 μM
Compound: 72, CFI-400936
|
Growth inhibition of human A549 cells after 5 days by SRB assay
Growth inhibition of human A549 cells after 5 days by SRB assay
|
[PMID: 25043312] |
| HCT-116 | EC50 |
0.52 μM
Compound: 72, CFI-400936
|
Inhibition of TTK in human HCT116 cells assessed as phosphorylation of histone H3 at Ser10 residue after 4 hrs by immunoassay
Inhibition of TTK in human HCT116 cells assessed as phosphorylation of histone H3 at Ser10 residue after 4 hrs by immunoassay
|
[PMID: 25043312] |
| HCT-116 | GI50 |
0.1 μM
Compound: 72, CFI-400936
|
Growth inhibition of human HCT116 cells after 5 days by SRB assay
Growth inhibition of human HCT116 cells after 5 days by SRB assay
|
[PMID: 25043312] |
| MDA-MB-468 | GI50 |
0.66 μM
Compound: 72, CFI-400936
|
Growth inhibition of human MDA-MB-468 cells after 5 days by SRB assay
Growth inhibition of human MDA-MB-468 cells after 5 days by SRB assay
|
[PMID: 25043312] |
Chemical Information
-
CAS No. 1338793-07-9
-
Molecular Weight 477.58
-
Formula C25H27N5O3S
-
SMILES
O=C(C(N(C)C)C1=C(CC)C=CC=C1)NC2=CC3=C(NN=C3C4=CC(S(=O)(N)=O)=CC=C4)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)